Navigation Links
Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Date:2/20/2008

- Review Based on MOSAIC Clinical Trial Demonstrating Significantly Improved Six-year Overall Survival in Stage III Colon Cancer Following

Surgery Compared to Standard Regimen Alone -

BRIDGEWATER, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and assigned priority review status to a supplemental new drug application (sNDA) that proposes changes to the Eloxatin(R) (oxaliplatin injection) prescribing information (PI) to include a six-year analysis from the MOSAIC trial. In the proposed PI changes, sanofi-aventis is seeking the inclusion of six-year overall survival and five-year disease free survival data in Stage III colon cancer patients treated with either FOLFOX4 (Eloxatin- based chemotherapy regimen) or standard infusional 5-FU/LV-based chemotherapy alone, following surgery to remove the primary tumor.

A priority review designation sets the target date for the completion of the FDA's review of the proposed changes at or before six months from the date of filing.

"We are pleased that FDA is giving priority review to our application for a label change to include updated six-year overall survival data," said Dr. Nassir Habboubi, Vice President of U.S. Medical Affairs, Oncology, for sanofi- aventis. "Inclusion of these data in the prescribing information would provide physicians with a more updated analysis than the existing PI and will help them better evaluate the use of prescribing an Eloxatin(R)-based chemotherapy regimen for their Stage III colon cancer patients."

In the MOSAIC trial, Stage III colon cancer patients treated after complete surgical resection of the tumor with Eloxatin in combination with infusional 5-FU/LV had a significant reduction (20%) in the risk of dying after a median of six years compared to standard 5FU/LV-based chemotherapy alone (hazard ratio of 0.80, confidence interval [0.65, 0.97],
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
2. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
5. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
6. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
7. Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
8. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
9. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
10. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
11. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... April 20, 2015 Pharmaceutical Research and Manufacturers ... billion last year in the research and development (R&D) ... the majority of all biopharmaceutical R&D spending – both ... States . The new R&D numbers, the result ... highlighted in the newly released PhRMA 2015 ...
(Date:4/20/2015)...  Purdue Pharma, a leading specialty pharmaceutical company, ... joined the company as Senior Vice President of ... for all of Purdue,s efforts to acquire or ... benefit from our patient-focused commercial capabilities. ... President & CEO Mark Timney . "Alan ...
(Date:4/20/2015)... LINCOLNSHIRE, Ill. , April 20, 2015  U.S. pharmacy ... are expected to drift into the low double-digits by 2016, ... global talent, retirement and health solutions business of Aon ... plan design changes are projected to be 9.5 percent in ... 2016. Aon Hewitt predicts a similar rate of ...
Breaking Medicine Technology:PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 2PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 3Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development 2Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 2Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 4
... Corp. (NASDAQ: KOOL ), a leading supplier of ... cells, said today that Mahendra Rao, M.D., Ph.D. has resigned ... Rao has been appointed to a position with the National ... a director of the Company, pursuant to NIH and federal ...
... 1, 2011 Merrimack Pharmaceuticals, Inc. announced today ... has granted MM-398 orphan drug status for the ... stable nanotherapeutic encapsulation of the marketed chemotherapy drug ... development and commercialization in Taiwan under the designation ...
Cached Medicine Technology:ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao 2ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao 3FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer 2
(Date:4/21/2015)... 2015 CALNOC, the nation’s first nursing ... RN, FAAN, will keynote their upcoming conference – Navigating ... CA on October 26, 2015. , Dr. Burnes ... of Nurse Executives (AONE) and the first African American ... American Academy of Nursing and the National Black Nurses ...
(Date:4/21/2015)... Renewable energy, sustainable living, the greening of ... Day topics USM Studios ’ programming covers in ... affect of climate change on the planet, the award-winning ... on the environmental concerns affecting the nation and world ... lifestyles, clean air options, and much more when the ...
(Date:4/21/2015)... TX (PRWEB) April 21, 2015 ... from a prestigious Illinois university for a second ... units (NICUs) more conducive to newborn infants’ cognitive ... top three NICU problems we have identified through ... care professionals,” said George Hutchinson, Invictus Medical’s Chief ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Heritage Woods ... host an Open House and Dine-and-Dash Spaghetti Dinner from ... The community, which is located in Centralia, Illinois, houses ... homes for low-income adults 55 and older. , Guests ... staff about supportive living options for seniors. After the ...
(Date:4/20/2015)... 21, 2015 Reality show stars, food, ... at the twentieth annual Michigan International Women’s Show, April ... , “There is lots to see and do from ... for fashion and gifts,” said Beth Anderson, executive show ... and encouraging with appearances from Randy Fenoli of ‘Say ...
Breaking Medicine News(10 mins):Health News:Nationally Recognized Nurse Leader Linda Burnes Bolton to Present Keynote Address at CALNOC Conference 2Health News:USM Studios’ Programming Focuses on the Environment 2Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 2Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 3
... Behen HealthDay Reporter , FRIDAY, Jan. 20 (HealthDay ... good job of informing American women with early stage breast ... surgery, a new study suggests. In the study, researchers ... on their knowledge of the disease. Respondents typically answered only ...
... Quitting smoking is never easy. However, when you,re poor ... hard, according to a new study by a tobacco ... (CCNY). Christine Sheffer, associate medical professor at CCNY,s ... different socioeconomic backgrounds after they had completed a statewide ...
... The Mount Sinai Medical Center in New York have ... known as phthalates and obesity in young children ... Phthalates are man-made, endocrine-disrupting chemicals that can ... in plastic flooring and wall coverings, food processing materials, ...
... ON When cancers become aggressive and spread they ... how to stop this development. A new imaging platform ... and John Lewis is providing insight into just that ... Certain proteins, such as E-cadherin, are important for ...
... per cent of patients hospitalized after a stroke develop delirium, ... Researchers found patients who experience delirium after stroke are five ... be discharged to a long-term care facility, nursing home or ... and prevention of delirium are important for a quick recovery, ...
... are the Robinson Crusoes of the intracellular world -- ... where their fellow chromosomes reside. Such castaways, each confined ... cells, but scientists haven,t known what role, if any, ... paper published online on Jan. 18 by the journal ...
Cached Medicine News:Health News:Many Breast Cancer Patients Uninformed About Options: Study 2Health News:Many Breast Cancer Patients Uninformed About Options: Study 3Health News:Poorest smokers face toughest odds for kicking the habit 2Health News:Exposure to chemical found in personal care products may contribute to childhood obesity 2Health News:Lawson researchers engineer a switch to tame aggressive cancers 2Health News:Study finds delirium after stroke linked to poorer outcomes for patients 2Health News:'Pulverized' chromosomes linked to cancer? 2Health News:'Pulverized' chromosomes linked to cancer? 3
... design allows "Four gels in one tank" electrophoresis. ... run 200 samples or more in one compact ... gels. To ensure even migration, the electrode height ... being run. Ideal for high throughput procedures, an ...
... tanks come with turn and cast gel ... pouring as simple as possible. , ... your application. Avaialble in a variety of ... gel size right up to the 20 ...
... UniPhor units can be used for: ... and non denaturing SDS-PAGE gels IEF ... Z64,075 1) Preparative Protein and Peptide ... gels IEF in Agarose Ampholyte Gels ...
... Horizontal Gel System provides a compact format ... DNA fragments, PCR products and synthetic oligonucleotides, ... The Mini Horizontal Unit has gel bed ... The gel bed is UV transparent. Adjustable ...
Medicine Products: